7.0 Protocol Review and Monitoring System (PRMS) Description The Cancer Protocol Review Committee (CPRC) functions as the Protocol Review and Monitoring System for the Masonic Cancer Center (MCC). The MCC Clinical Research Leadership (CRL) appoints the chair of the CPRC. Committee members may be selected by the CRL or the CPRC chair. Members are selected by area of expertise to form a diversified group of clinicians and other professionals able to provide rigorous scientific review of study rationale and design. The CPRC membership is divided into 2 subcommittees: the Therapeutic Interventional Committee, which meets twice monthly, and the Non-Therapeutic Interventional Committee, which meets monthly. The MCC Clinical Trials Office provides administrative support to both CPRC subcommittees. Protocol prioritization has been emphasized during the last granting period to ensure greater efficiency of clinical trial management and to optimize patient enrollment. Prior to CPRC review, protocols or protocol concepts are sent to the appropriate interdisciplinary site-specific cancer care (ISC) team for review. The purpose of the ISC teams is to identify the needs of the patients they see;identify appropriate clinical trials to address these needs from industry. Cooperative Group, and investigator-initiated resources;and prioritize enrollment of patients in clinical trials. The CPRC reviews each study with regard to the following criteria, and can approve, approve with stipulations, defer, or disapprove each study: * Purpose of study * Justification of study, including results of previous studies or pilot data * Inclusion/exclusion requirements * Treatment plan, including doses, dose adjustments, schedule, and duration * Description of all drugs, including chemical formula when available, known toxicities, methods of procurement, methods of storage, and other relevant information * Adequacy of the data and safety monitoring plan * Biostatistical support (investigator-initiated trials only) * Adequacy of the statistical section Time to protocol approval continues to be monitored with the aim of expediting clinical trial implementation. Ongoing post-approval review includes review of amendments, annual review, and accrual reviews.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Minnesota Twin Cities
United States
Zip Code
Abbott, Kenneth L; Nyre, Erik T; Abrahante, Juan et al. (2015) The Candidate Cancer Gene Database: a database of cancer driver genes from forward genetic screens in mice. Nucleic Acids Res 43:D844-8
Yee, Douglas (2015) A tale of two receptors: insulin and insulin-like growth factor signaling in cancer. Clin Cancer Res 21:667-9
Daniel, A R; Gaviglio, A L; Knutson, T P et al. (2015) Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes. Oncogene 34:506-15
Upadhyaya, Pramod; Hecht, Stephen S (2015) Quantitative analysis of 3'-hydroxynorcotinine in human urine. Nicotine Tob Res 17:524-9
Patel, Yesha M; Stram, Daniel O; Wilkens, Lynne R et al. (2015) The contribution of common genetic variation to nicotine and cotinine glucuronidation in multiple ethnic/racial populations. Cancer Epidemiol Biomarkers Prev 24:119-27
Chen, Liddy M; Ibrahim, Joseph G; Chu, Haitao (2014) Flexible stopping boundaries when changing primary endpoints after unblinded interim analyses. J Biopharm Stat 24:817-33
Takahashi, Yutaka; Hui, Susanta K (2014) Fast, simple, and informative patient-specific dose verification method for intensity modulated total marrow irradiation with helical tomotherapy. Radiat Oncol 9:34
Cooley, Sarah; Weisdorf, Daniel J; Guethlein, Lisbeth A et al. (2014) Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia. J Immunol 192:4592-600
Gorden, Brandi H; Kim, Jong-Hyuk; Sarver, Aaron L et al. (2014) Identification of three molecular and functional subtypes in canine hemangiosarcoma through gene expression profiling and progenitor cell characterization. Am J Pathol 184:985-95
Landman, Sean R; Hwang, Tae Hyun; Silverstein, Kevin A T et al. (2014) SHEAR: sample heterogeneity estimation and assembly by reference. BMC Genomics 15:84

Showing the most recent 10 out of 319 publications